BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Szabo ST, Thorpy MJ, Mayer G, Peever JH, Kilduff TS. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy. Sleep Med Rev 2019;43:23-36. [PMID: 30503715 DOI: 10.1016/j.smrv.2018.09.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Giannoccaro MP, Sallemi G, Liguori R, Plazzi G, Pizza F. Immunotherapy in Narcolepsy. Curr Treat Options Neurol 2020;22:2. [PMID: 31997035 DOI: 10.1007/s11940-020-0609-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Harwell V, Fasinu PS. Pitolisant and Other Histamine-3 Receptor Antagonists-An Update on Therapeutic Potentials and Clinical Prospects. Medicines (Basel) 2020;7:E55. [PMID: 32882898 DOI: 10.3390/medicines7090055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Thorpy MJ, Ohayon MM, Carls G, Black J, Pasta DJ, Hyman DL, Villa KF. Assessing the impact of sodium oxybate treatment on functioning, productivity, and health-related quality of life in patients with narcolepsy: findings from the Nexus Narcolepsy Registry (waves 1-4). Sleep Med 2021;84:380-8. [PMID: 34247126 DOI: 10.1016/j.sleep.2021.06.010] [Reference Citation Analysis]
4 Yang J, Zhang L, Hou Y, Wei Q, Ou R, Lin J, Song W, Cao B, Shang H. Excessive daytime sleepiness in idiopathic blepharospasm. Parkinsonism Relat Disord 2021;89:134-8. [PMID: 34298213 DOI: 10.1016/j.parkreldis.2021.07.005] [Reference Citation Analysis]
5 Cuomo MC, Sheehan AH, Jordan JK. Solriamfetol for the Management of Excessive Daytime Sleepiness. J Pharm Pract 2021;:8971900211009080. [PMID: 33882756 DOI: 10.1177/08971900211009080] [Reference Citation Analysis]
6 Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Morales-Lara D, Mechoulam R, Drucker-Colín R. Cannabidiol Partially Blocks the Excessive Sleepiness in Hypocretindeficient Rats: Preliminary Data. CNS Neurol Disord Drug Targets 2019;18:705-12. [PMID: 31642794 DOI: 10.2174/1871527318666191021143300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Nirogi R, Benade V, Daripelli S, Subramanian R, Kamuju V, Bhyrapuneni G, Muddana NR, Mekala VR, Petlu S, Jayarajan P, Badange R, Shinde A, Jasti V. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation. Psychopharmacology (Berl) 2021;238:1495-511. [PMID: 33550481 DOI: 10.1007/s00213-021-05779-x] [Reference Citation Analysis]
8 Meskill GJ, Kallweit U, Zarycranski D, Caussé C, Finance O, Ligneau X, Davis CW. Pitolisant for the treatment of cataplexy in adults with narcolepsy. Expert Opinion on Orphan Drugs. [DOI: 10.1080/21678707.2021.2022472] [Reference Citation Analysis]
9 Krystal AD, Prather AA. Sleep Pharmacogenetics: The Promise of Precision Medicine. Sleep Med Clin 2019;14:317-31. [PMID: 31375201 DOI: 10.1016/j.jsmc.2019.05.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Markham A. Solriamfetol: First Global Approval. Drugs 2019;79:785-90. [DOI: 10.1007/s40265-019-01123-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
11 Yeh JY, Shyu YC, Lee SY, Yuan SS, Yang CJ, Yang KC, Lee TL, Sun CC, Wang LJ. Comorbidity of Narcolepsy and Psychotic Disorders: A Nationwide Population-Based Study in Taiwan. Front Psychiatry 2020;11:205. [PMID: 32269533 DOI: 10.3389/fpsyt.2020.00205] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Dong YJ, Jiang NH, Zhan LH, Teng X, Fang X, Lin MQ, Xie ZY, Luo R, Li LZ, Li B, Zhang BB, Lv GY, Chen SH. Soporific effect of modified Suanzaoren Decoction on mice models of insomnia by regulating Orexin-A and HPA axis homeostasis. Biomed Pharmacother 2021;143:112141. [PMID: 34509822 DOI: 10.1016/j.biopha.2021.112141] [Reference Citation Analysis]
13 Heidbreder A, Dirks C, Ramm M. Therapy for Cataplexy. Curr Treat Options Neurol 2020;22. [DOI: 10.1007/s11940-020-0619-5] [Reference Citation Analysis]
14 Ferri R, Mogavero MP, Bruni O, Plazzi G, Schenck CH, DelRosso LM. Increased Chin Muscle Tone during All Sleep Stages in Children Taking SSRI Antidepressants and in Children with Narcolepsy Type 1. Sleep 2021:zsab147. [PMID: 34111296 DOI: 10.1093/sleep/zsab147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Liang Y, Shi W, Xiang A, Hu D, Wang L, Zhang L. The NAergic locus coeruleus-ventrolateral preoptic area neural circuit mediates rapid arousal from sleep. Curr Biol 2021:S0960-9822(21)00826-5. [PMID: 34270948 DOI: 10.1016/j.cub.2021.06.031] [Reference Citation Analysis]
16 Chaiard J, Weaver TE. Update on Research and Practices in Major Sleep Disorders: Part II-Insomnia, Willis-Ekbom Disease (Restless Leg Syndrome), and Narcolepsy. J Nurs Scholarsh 2019;51:624-33. [PMID: 31524329 DOI: 10.1111/jnu.12515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Shen C, Li X, Ma P, Li H, Xiao B, Cai W, Xing X. Nicotinamide mononucleotide (NMN) and NMN-rich product supplementation alleviate p-chlorophenylalanine-induced sleep disorders. Journal of Functional Foods 2022;91:105031. [DOI: 10.1016/j.jff.2022.105031] [Reference Citation Analysis]
18 Ollila HM. Narcolepsy type 1: what have we learned from genetics? Sleep 2020;43:zsaa099. [PMID: 32442260 DOI: 10.1093/sleep/zsaa099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Zhang Y, Ren R, Yang L, Zhang H, Shi Y, Sanford LD, Tang X. Polysomnographic nighttime features of narcolepsy: A systematic review and meta-analysis. Sleep Med Rev 2021;58:101488. [PMID: 33934047 DOI: 10.1016/j.smrv.2021.101488] [Reference Citation Analysis]
20 Thorpy MJ. Recently Approved and Upcoming Treatments for Narcolepsy. CNS Drugs 2020;34:9-27. [PMID: 31953791 DOI: 10.1007/s40263-019-00689-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
21 El-Solh AA, Rudraraju A, Pasrija D, Bui H. Pharmacotherapy of residual excessive sleepiness among continuous positive airway pressure (CPAP) treated patients with sleep apnea. Expert Opin Pharmacother 2022;:1-10. [PMID: 35045769 DOI: 10.1080/14656566.2022.2029408] [Reference Citation Analysis]
22 Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med 2020;68:97-109. [PMID: 32032921 DOI: 10.1016/j.sleep.2019.09.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
23 Akpa B, Lee K. Update on Novel Medications to Treat Narcolepsy. Curr Sleep Medicine Rep 2020;6:189-97. [DOI: 10.1007/s40675-020-00178-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Barateau L, Jaussent I, Roeser J, Ciardiello C, Kilduff TS, Dauvilliers Y. Cerebrospinal fluid monoamine levels in central disorders of hypersomnolence. Sleep 2021;44:zsab012. [PMID: 33476396 DOI: 10.1093/sleep/zsab012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Giannoccaro MP, Liguori R, Plazzi G, Pizza F. Reviewing the Clinical Implications of Treating Narcolepsy as an Autoimmune Disorder. Nat Sci Sleep 2021;13:557-77. [PMID: 34007229 DOI: 10.2147/NSS.S275931] [Reference Citation Analysis]
26 Amadei E, Cantile C, Gazzano A, Pierantoni L, Mariti C. The link between neurology and behavior in veterinary medicine: A review. Journal of Veterinary Behavior 2021;46:40-53. [DOI: 10.1016/j.jveb.2021.07.003] [Reference Citation Analysis]
27 Carreira H, Williams R, Strongman H, Bhaskaran K. Identification of mental health and quality of life outcomes in primary care databases in the UK: a systematic review. BMJ Open 2019;9:e029227. [PMID: 31270119 DOI: 10.1136/bmjopen-2019-029227] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Zager A. Modulating the immune response with the wake-promoting drug modafinil: A potential therapeutic approach for inflammatory disorders. Brain Behav Immun 2020;88:878-86. [PMID: 32311496 DOI: 10.1016/j.bbi.2020.04.038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
29 Li S, Yang J. Pitolisant for treating patients with narcolepsy. Expert Review of Clinical Pharmacology 2020;13:79-84. [DOI: 10.1080/17512433.2020.1714435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Yuan S, Yu B, Liu H. New drug approvals for 2019: Synthesis and clinical applications. European Journal of Medicinal Chemistry 2020;205:112667. [DOI: 10.1016/j.ejmech.2020.112667] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Pérez-carbonell L. Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy. Curr Treat Options Neurol 2019;21. [DOI: 10.1007/s11940-019-0595-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Williams RH, Tsunematsu T, Thomas AM, Bogyo K, Yamanaka A, Kilduff TS. Transgenic Archaerhodopsin-3 Expression in Hypocretin/Orexin Neurons Engenders Cellular Dysfunction and Features of Type 2 Narcolepsy. J Neurosci 2019;39:9435-52. [PMID: 31628177 DOI: 10.1523/JNEUROSCI.0311-19.2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]